Envoy Medical (COCH) Common Equity (2020 - 2026)

Envoy Medical has disclosed Common Equity across 7 years of filings, most recently posting $3.3 million for Q2 2026.

• In Q2 2026, Common Equity rose 111.06% year-over-year to $3.3 million; the TTM figure through Jun 2026 stood at $3.3 million (up 111.06% YoY), while the FY2025 annual figure was -$12.2 million, up 35.47% from the prior year.
• Common Equity came in at $3.3 million for Q2 2026 at Envoy Medical, down from $10.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $10.2 million in Q1 2026 to a low of -$47.5 million in Q1 2023.
• Average Common Equity over 5 years is -$17.8 million, with a median of -$18.7 million recorded in 2024.
• Year-over-year, Common Equity sank 960.92% in 2024 and soared 141.95% in 2026.
• Over 5 years, Common Equity stood at -$36.2 million in 2022, then jumped by 95.09% to -$1.8 million in 2023, then slumped by 960.92% to -$18.8 million in 2024, then surged by 35.47% to -$12.2 million in 2025, then soared by 127.17% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $3.3 million in Q2 2026, $10.2 million in Q1 2026, and -$12.2 million in Q4 2025.